BIOTECH ASSISTANT / FIELD NOTES

Breviscapine–borneol cocrystal study reports higher exposure in rats

Academic source · Natural Products and Bioprospecting

Source published: 2026-11-02

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

Researchers report preparing a breviscapine–borneol cocrystal by solvent evaporation, supported by solid-state characterization and calculations. The abstract describes synchronized release and rat pharmacokinetic testing: exposure was 1.6 times that of bulk breviscapine, with peak concentration rising from 0.8 to 1.2 mg/L. These preclinical findings do not establish clinical benefit or human bioavailability.

Why this paper is included

Potential business implication: coordinated release of an active ingredient and absorption enhancer may warrant formulation screening, with further structural and translational validation.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Pharmaceutical solid state Formulation Development & Manufacturing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

XtalPi Asymchem WuXi AppTec / WuXi TIDES Porton Pharma Almac

Explore field companies →Explore literature →

Related updates

2026-11-06Journal of Pharmaceutical Health Care and Sciences

Crushed tadalafil formulation retains measured solid-state properties during a 90-day storage study

Japanese researchers evaluated crushed tadalafil tablets mixed with lactose at 40 mg/g during 90 days at 25°C under defined humidity and lighting conditions. Thermal analysis and powder X-ray diffraction showed no appreciable changes in thermal behavior or crystalline state. The findings concern the tested preparation and conditions; they do not establish clinical equivalence or a general storage period for other formulations.

Formulation Development & Manufacturing Pharmaceutical solid state Ask AI ↗

2026-11-04Crystal Pharmatech / PR Newswire

Crystal Pharmatech updates ED-1 service information in November 4 English announcement

Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.

Companies mentionedCrystal Pharmatech ↗ELDICO Scientific ↗

MicroED structure determination Pharmaceutical solid state Ask AI ↗

2026-11-03Frontiers in Chemistry

Review examines cocrystal performance and barriers to clinical translation

A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.

Pharmaceutical solid state Formulation Development & Manufacturing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗